{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:55:41Z","timestamp":1790582141476,"version":"4.1.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08839-y","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:55:22Z","timestamp":1788972922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic role of molecular imaging and genomics in thyroid cancer management: from diagnosis to personalized treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Samaneh","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hoseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnaz Sadat","family":"Ravari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobeh","family":"Zarei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pejman","family":"Shahrokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"13","key":"8839_CR1","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.3390\/cancers13133188","volume":"13","author":"Y Jin","year":"2021","unstructured":"Jin Y, Liu B, Younis MH, Huang G, Liu J, Cai W, et al. Next-generation molecular imaging of thyroid cancer. Cancers. 2021;13(13):3188.","journal-title":"Cancers"},{"key":"8839_CR2","doi-asserted-by":"publisher","first-page":"122110","DOI":"10.1016\/j.lfs.2023.122110","volume":"332","author":"S Bhattacharya","year":"2023","unstructured":"Bhattacharya S, Mahato RK, Singh S, Bhatti GK, Mastana SS, Bhatti JS. Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches. Life Sci. 2023;332:122110.","journal-title":"Life Sci"},{"issue":"10387","key":"8839_CR3","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","volume":"401","author":"DW Chen","year":"2023","unstructured":"Chen DW, Lang BH, McLeod DS, Newbold K, Haymart MR. Thyroid cancer. Lancet. 2023;401(10387):1531\u201344.","journal-title":"Lancet"},{"issue":"13","key":"8839_CR4","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","volume":"11","author":"JM Oh","year":"2021","unstructured":"Oh JM, Ahn B-C. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics. 2021;11(13):6251.","journal-title":"Theranostics"},{"issue":"4","key":"8839_CR5","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3390\/ijms22041950","volume":"22","author":"J Hu","year":"2021","unstructured":"Hu J, Yuan IJ, Mirshahidi S, Simental A, Lee SC, Yuan X. Thyroid carcinoma: phenotypic features, underlying biology and potential relevance for targeting therapy. Int J Mol Sci. 2021;22(4):1950.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"8839_CR6","first-page":"11","volume":"174","author":"K Dhuli","year":"2023","unstructured":"Dhuli K, Medori M, Donato K, Maltese P, Tanzi B, Tezzele S, et al. Omics sciences and precision medicine in thyroid cancer. Clin Ter. 2023;174(6):11\u201320.","journal-title":"Clin Ter"},{"issue":"2","key":"8839_CR7","doi-asserted-by":"publisher","first-page":"104116","DOI":"10.1016\/j.lpm.2022.104116","volume":"51","author":"L Giovanella","year":"2022","unstructured":"Giovanella L, Avram AM, Ov\u010dari\u010dek PP, Clerc J. Thyroid functional and molecular imaging. La Presse M\u00e9dicale. 2022;51(2):104116.","journal-title":"La Presse M\u00e9dicale"},{"issue":"12","key":"8839_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/14789450.2023.2288222","volume":"20","author":"I Piga","year":"2023","unstructured":"Piga I, L\u2019Imperio V, Capitoli G, Denti V, Smith A, Magni F, et al. Paving the path toward multi-omics approaches in the diagnostic challenges faced in thyroid pathology. Expert Rev Proteomics. 2023;20(12):419\u201337.","journal-title":"Expert Rev Proteomics"},{"key":"8839_CR9","doi-asserted-by":"crossref","unstructured":"Nguyen NC, Anigati EM, Desai NB, \u00d6z OK, editors. Radioactive iodine therapy in differentiated thyroid cancer: an update on dose recommendations and risk of secondary primary malignancies. Seminars in Nuclear Medicine. Elsevier; 2024.","DOI":"10.1053\/j.semnuclmed.2024.05.002"},{"issue":"5","key":"8839_CR10","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/cancers14051272","volume":"14","author":"L Giovanella","year":"2022","unstructured":"Giovanella L, Deandreis D, Vrachimis A, Campenni A, Petranovic Ovcaricek P. Molecular imaging and theragnostics of thyroid cancers. Cancers. 2022;14(5):1272.","journal-title":"Cancers"},{"issue":"7","key":"8839_CR11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3390\/diagnostics12071763","volume":"12","author":"M Pacilio","year":"2022","unstructured":"Pacilio M, Conte M, Frantellizzi V, De Feo MS, Pisani AR, Marongiu A, et al. Personalized dosimetry in the context of radioiodine therapy for differentiated thyroid cancer. Diagnostics. 2022;12(7):1763.","journal-title":"Diagnostics"},{"issue":"2","key":"8839_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/RLU.0000000000004431","volume":"48","author":"P Kumar","year":"2023","unstructured":"Kumar P, Damle NA, Bal C. Radioiodine therapy in pediatric differentiated thyroid cancer: dosimetry, clinical care, and future challenges. Clin Nucl Med. 2023;48(2):158\u201367.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"8839_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/cancers17030425","volume":"17","author":"R Pishdad","year":"2025","unstructured":"Pishdad R, Santhanam P. Current and Emerging Radiotracers and Technologies for Detection of Advanced Differentiated Thyroid Cancer: A Narrative Review. Cancers. 2025;17(3):425.","journal-title":"Cancers"},{"issue":"4","key":"8839_CR14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/cancers14041055","volume":"14","author":"V Ambrosini","year":"2022","unstructured":"Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, et al. Radiolabeled somatostatin analogues for diagnosis and treatment of neuroendocrine tumors. Cancers. 2022;14(4):1055.","journal-title":"Cancers"},{"issue":"15","key":"8839_CR15","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.3390\/molecules27154936","volume":"27","author":"C Sakulpisuti","year":"2022","unstructured":"Sakulpisuti C, Charoenphun P, Chamroonrat W. Positron emission tomography radiopharmaceuticals in differentiated thyroid cancer. Molecules. 2022;27(15):4936.","journal-title":"Molecules"},{"key":"8839_CR16","unstructured":"Troshin T. Molecular mechanisms of differentiated thyroid cancer. PQDT-Global; 2024."},{"issue":"19","key":"8839_CR17","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.3390\/cancers15194865","volume":"15","author":"N Sahakian","year":"2023","unstructured":"Sahakian N, Castinetti F, Romanet P. Molecular basis and natural history of medullary thyroid cancer: it is (almost) all in the RET. Cancers. 2023;15(19):4865.","journal-title":"Cancers"},{"issue":"11","key":"8839_CR18","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.3390\/ijms22115744","volume":"22","author":"E Bonaldi","year":"2021","unstructured":"Bonaldi E, Gargiuli C, De Cecco L, Micali A, Rizzetti MG, Greco A, et al. BRAF inhibitors induce feedback activation of RAS pathway in thyroid cancer cells. Int J Mol Sci. 2021;22(11):5744.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"8839_CR19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3390\/cancers15030710","volume":"15","author":"L Schubert","year":"2023","unstructured":"Schubert L, Mariko ML, Clerc J, Huillard O, Groussin L. MAPK pathway inhibitors in thyroid cancer: preclinical and clinical data. Cancers. 2023;15(3):710.","journal-title":"Cancers"},{"key":"8839_CR20","doi-asserted-by":"publisher","first-page":"1099280","DOI":"10.3389\/fonc.2022.1099280","volume":"12","author":"G Elia","year":"2022","unstructured":"Elia G, Patrizio A, Ragusa F, Paparo SR, Mazzi V, Balestri E, et al. Molecular features of aggressive thyroid cancer. Front Oncol. 2022;12:1099280.","journal-title":"Front Oncol"},{"issue":"2","key":"8839_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1677\/erc.1.0978","volume":"12","author":"M Xing","year":"2005","unstructured":"Xing M. BRAF mutation in thyroid cancer. Endocrine-related Cancer. 2005;12(2):245\u201362.","journal-title":"Endocrine-related Cancer"},{"issue":"5","key":"8839_CR22","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/pharmaceutics14051040","volume":"14","author":"F Cuomo","year":"2022","unstructured":"Cuomo F, Giani C, Cobellis G. The role of the kinase inhibitors in thyroid cancers. Pharmaceutics. 2022;14(5):1040.","journal-title":"Pharmaceutics"},{"issue":"15","key":"8839_CR23","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.3390\/cancers13153785","volume":"13","author":"V Marotta","year":"2021","unstructured":"Marotta V, Bifulco M, Vitale M. Significance of RAS mutations in thyroid benign nodules and non-medullary thyroid cancer. Cancers. 2021;13(15):3785.","journal-title":"Cancers"},{"issue":"2","key":"8839_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00432-020-03491-5","volume":"147","author":"M Liu","year":"2021","unstructured":"Liu M, Chen P, Hu H-Y, Ou-Yang D-J, Khushbu R-a, Tan H-l, et al. Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer. J Cancer Res Clin Oncol. 2021;147(2):323\u201337.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"8839_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12672-016-0256-3","volume":"7","author":"AS Alzahrani","year":"2016","unstructured":"Alzahrani AS, Alsaadi R, Murugan AK, Sadiq BB. TERT promoter mutations in thyroid cancer. Horm Cancer. 2016;7(3):165\u201377.","journal-title":"Horm Cancer"},{"issue":"22","key":"8839_CR26","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s00018-008-8170-7","volume":"65","author":"M Krishna","year":"2008","unstructured":"Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci. 2008;65(22):3525\u201344.","journal-title":"Cell Mol Life Sci"},{"key":"8839_CR27","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.bbamcr.2006.10.005","volume":"1773","author":"YD S","year":"2007","unstructured":"YD S. The MEK\/ERK cascade: From signaling specificity to diverse functions. Biochim Biophys Acta. 2007;1773:1213\u201326.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"8839_CR28","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1530\/JOE-17-0266","volume":"235","author":"MA Zaballos","year":"2017","unstructured":"Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol. 2017;235(2):R43\u201361.","journal-title":"J Endocrinol"},{"issue":"7","key":"8839_CR29","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454\u20137.","journal-title":"Cancer Res"},{"issue":"11","key":"8839_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nrm1498","volume":"5","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875\u201385.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8839_CR31","unstructured":"Trinh NT. Prognostic factors for persistent or recurrent disease in differentiated thyroid cancer: a systematic review. PQDT-Global. 2022."},{"issue":"1","key":"8839_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.surg.2022.05.048","volume":"173","author":"JB Liu","year":"2023","unstructured":"Liu JB, Ramonell KM, Carty SE, McCoy KL, Schaitkin BM, Karslioglu-French E, et al. Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes. Surgery. 2023;173(1):252\u20139.","journal-title":"Surgery"},{"key":"8839_CR33","doi-asserted-by":"publisher","first-page":"1270796","DOI":"10.3389\/fendo.2023.1270796","volume":"14","author":"N Mukhtar","year":"2023","unstructured":"Mukhtar N, Alhamoudi K, Alswailem M, Alhindi H, Murugan AK, Alghamdi B, et al. How do BRAF V600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer? Front Endocrinol. 2023;14:1270796.","journal-title":"Front Endocrinol"},{"key":"8839_CR34","doi-asserted-by":"publisher","first-page":"688370","DOI":"10.3389\/fcell.2021.688370","volume":"9","author":"X Dong","year":"2022","unstructured":"Dong X, Akuetteh PDP, Song J, Ni C, Jin C, Li H, et al. Major vault protein (MVP) associated with BRAF V600E mutation is an immune microenvironment-related biomarker promoting the progression of papillary thyroid cancer via MAPK\/ERK and PI3K\/AKT pathways. Front Cell Dev Biology. 2022;9:688370.","journal-title":"Front Cell Dev Biology"},{"issue":"8","key":"8839_CR35","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s40618-023-02293-z","volume":"47","author":"C He","year":"2024","unstructured":"He C, Li Y, Gan L, Lin Y, Zhang B, Ma L, et al. Notch signaling regulates Th17 cells differentiation through PI3K\/AKT\/mTORC1 pathway and involves in the thyroid injury of autoimmune thyroiditis. J Endocrinol Investig. 2024;47(8):1971\u201386.","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"8839_CR36","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3892\/mmr.2021.12249","volume":"24","author":"J Lv","year":"2021","unstructured":"Lv J, Liu C, Chen F-K, Feng Z-P, Jia L, Liu P-J, et al. M2-like tumour-associated macrophage-secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K\/AKT\/mTOR pathway. Mol Med Rep. 2021;24(2):604.","journal-title":"Mol Med Rep"},{"issue":"4","key":"8839_CR37","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-06-1125","volume":"13","author":"P Hou","year":"2007","unstructured":"Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase\/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161\u201370.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"8839_CR38","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1210\/jc.2004-2281","volume":"90","author":"G Wu","year":"2005","unstructured":"Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metabolism. 2005;90(8):4688\u201393.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"9","key":"8839_CR39","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1210\/jc.2005-1726","volume":"90","author":"D Liu","year":"2005","unstructured":"Liu D, Mambo E, Ladenson PW, Xing M. Letter re: uncommon mutation but common amplifications of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metabolism. 2005;90(9):5509.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"8839_CR40","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Investig. 2016;126(3):1052\u201366.","journal-title":"J Clin Investig"},{"issue":"3","key":"8839_CR41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1158\/0008-5472.CAN-06-3524","volume":"67","author":"N Yeager","year":"2007","unstructured":"Yeager N, Klein-Szanto A, Kimura S, Di Cristofano A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res. 2007;67(3):959\u201366.","journal-title":"Cancer Res"},{"issue":"1","key":"8839_CR42","doi-asserted-by":"publisher","first-page":"23719","DOI":"10.1038\/s41598-024-75087-9","volume":"14","author":"G Tan","year":"2024","unstructured":"Tan G, Jin B, Qian X, Wang Y, Zhang G, Agyekum EA, et al. TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer. Sci Rep. 2024;14(1):23719.","journal-title":"Sci Rep"},{"issue":"11","key":"8839_CR43","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1507\/endocrj.EJ23-0136","volume":"70","author":"M Matsuse","year":"2023","unstructured":"Matsuse M, Mitsutake N. TERT promoter mutations in thyroid cancer. Endocr J. 2023;70(11):1035\u201349.","journal-title":"Endocr J"},{"issue":"3","key":"8839_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.eprac.2021.12.005","volume":"28","author":"Z-Z Mu","year":"2022","unstructured":"Mu Z-Z, Zhang Y-Q, Sun D, Lu T, Lin Y-S. Effect of BRAFV600E and TERT promoter mutations on thyroglobulin response in patients with distant-metastatic differentiated thyroid cancer. Endocr Pract. 2022;28(3):265\u201370.","journal-title":"Endocr Pract"},{"key":"8839_CR45","first-page":"139","volume-title":"Thyroid FNA cytology: differential diagnoses and pitfalls","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang L, Liu Z. Molecular classification of thyroid tumors and key molecular features to identify high-grade thyroid carcinomas. In: Kakudo K, Liu Z, Jung CK, Hirokawa M, Bychkov A, Lai CR, editors. Thyroid FNA cytology: differential diagnoses and pitfalls. Springer; 2024. p. 139\u201346."},{"issue":"3","key":"8839_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41388-023-02889-y","volume":"43","author":"H Lasolle","year":"2024","unstructured":"Lasolle H, Schiavo A, Tourneur A, Gillotay P, De Faria Da Fonseca B, Ceolin L, et al. Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids. Oncogene. 2024;43(3):155\u201370.","journal-title":"Oncogene"},{"key":"8839_CR47","doi-asserted-by":"publisher","first-page":"643151","DOI":"10.3389\/fendo.2021.643151","volume":"12","author":"VR da Costa","year":"2021","unstructured":"da Costa VR, Bim LV, Pacheco e Silva LDP, Colloza-Gama GA, Bastos AU, Delcelo R, et al. Advances in detecting low prevalence somatic TERT promoter mutations in papillary thyroid carcinoma. Front Endocrinol. 2021;12:643151.","journal-title":"Front Endocrinol"},{"issue":"2","key":"8839_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jmoldx.2020.10.016","volume":"23","author":"M Hysek","year":"2021","unstructured":"Hysek M, Jatta K, Hellgren LS, Stenman A, Larsson C, Zedenius J, et al. Spatial distribution patterns of clinically relevant TERT promoter mutations in follicular thyroid tumors of uncertain malignant potential: advantages of the digital droplet PCR technique. J Mol Diagn. 2021;23(2):212\u201322.","journal-title":"J Mol Diagn"},{"issue":"1","key":"8839_CR49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12935-024-03459-2","volume":"24","author":"S Li","year":"2024","unstructured":"Li S, Hu G, Chen Y, Sang Y, Tang Q, Liu R. TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancer. Cancer Cell Int. 2024;24(1):271.","journal-title":"Cancer Cell Int"},{"key":"8839_CR50","doi-asserted-by":"publisher","first-page":"1474267","DOI":"10.3389\/fonc.2024.1474267","volume":"14","author":"EM Sabi","year":"2024","unstructured":"Sabi EM. The role of genetic and epigenetic modifications as potential biomarkers in the diagnosis and prognosis of thyroid cancer. Front Oncol. 2024;14:1474267.","journal-title":"Front Oncol"},{"issue":"1","key":"8839_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1875692120666230222110736","volume":"20","author":"A Mohammadi","year":"2023","unstructured":"Mohammadi A, Ahmadi SAY, Nekouian R. Papillary Thyroid Carcinoma: A Narrative Review on the Most Important Genetic and Epigenetic Alterations. Curr Pharmacogenom Personal Med. 2023;20(1):3\u201312.","journal-title":"Curr Pharmacogenom Personal Med"},{"issue":"31","key":"8839_CR52","doi-asserted-by":"publisher","first-page":"eabf3657","DOI":"10.1126\/sciadv.abf3657","volume":"7","author":"H Luo","year":"2021","unstructured":"Luo H, Xia X, Kim GD, Liu Y, Xue Z, Zhang L, et al. Characterizing dedifferentiation of thyroid cancer by integrated analysis. Sci Adv. 2021;7(31):eabf3657.","journal-title":"Sci Adv"},{"key":"8839_CR53","doi-asserted-by":"publisher","first-page":"1267499","DOI":"10.3389\/fendo.2023.1267499","volume":"14","author":"E Minna","year":"2023","unstructured":"Minna E, Devecchi A, Pistore F, Paolini B, Mauro G, Penso DA, et al. Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors. Front Endocrinol. 2023;14:1267499.","journal-title":"Front Endocrinol"},{"issue":"23","key":"8839_CR54","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.3390\/jcm13237161","volume":"13","author":"I-A Voinea","year":"2024","unstructured":"Voinea I-A, Petrova E, Dumitru N, Cocolo\u0219 A, Ioachim D, Goldstein AL, et al. Pathogenesis and management strategies in radioiodine-refractory differentiated thyroid cancer: From molecular mechanisms toward therapeutic approaches: A comprehensive review. J Clin Med. 2024;13(23):7161.","journal-title":"J Clin Med"},{"issue":"1","key":"8839_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11154-023-09836-y","volume":"25","author":"A Imperiale","year":"2024","unstructured":"Imperiale A, Berti V, Burgy M, Cazzato RL, Piccardo A, Treglia G. Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities. Reviews Endocr Metabolic Disorders. 2024;25(1):187\u2013202.","journal-title":"Reviews Endocr Metabolic Disorders"},{"issue":"1","key":"8839_CR56","first-page":"318","volume":"70","author":"M Nikkhah","year":"2023","unstructured":"Nikkhah M, Karami S, Khatami SH, Taheri-Anganeh M, Savardashtaki A, Mahmoodzadeh A, et al. Review of electrochemical and optical biosensors for testosterone measurement. Biotechnol Appl Chem. 2023;70(1):318\u201329.","journal-title":"Biotechnol Appl Chem"},{"key":"8839_CR57","doi-asserted-by":"publisher","first-page":"899575","DOI":"10.3389\/fendo.2022.899575","volume":"13","author":"Q Chen","year":"2022","unstructured":"Chen Q, Lin M, Wu S, Validating, Comparing C-TIRADS. K-TIRADS and ACR-TIRADS in Stratifying the Malignancy Risk of Thyroid Nodules. Front Endocrinol. 2022;13:899575.","journal-title":"Front Endocrinol"},{"key":"8839_CR58","doi-asserted-by":"crossref","unstructured":"Schenke S, Seifert P, Zimny M, Winkens T, Binse I, G\u00f6rges R. Risk Stratification of Thyroid Nodules Using the Thyroid Imaging Reporting and Data System (TIRADS): the omission of thyroid scintigraphy increases the rate of falsely suspected lesions. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2019;60(3):342\u20137.","DOI":"10.2967\/jnumed.118.211912"},{"issue":"1","key":"8839_CR59","first-page":"209","volume":"11","author":"G Anil","year":"2011","unstructured":"Anil G, Hegde A, Chong FH. Thyroid nodules: risk stratification for malignancy with ultrasound and guided biopsy. Cancer imaging: official publication Int Cancer Imaging Soc. 2011;11(1):209\u201323.","journal-title":"Cancer imaging: official publication Int Cancer Imaging Soc"},{"key":"8839_CR60","doi-asserted-by":"crossref","unstructured":"Rago T, Vitti P. Risk stratification of thyroid nodules: from ultrasound features to TIRADS. Cancers (Basel). 2022;14(3).","DOI":"10.3390\/cancers14030717"},{"issue":"1","key":"8839_CR61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13044-023-00155-7","volume":"16","author":"AP Borges","year":"2023","unstructured":"Borges AP, Antunes C, Caseiro-Alves F, Donato P. Analysis of 665 thyroid nodules using both EU-TIRADS and ACR TI-RADS classification systems. Thyroid Res. 2023;16(1):12.","journal-title":"Thyroid Res"},{"issue":"2","key":"8839_CR62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","volume":"20","author":"I Landa","year":"2024","unstructured":"Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Reviews Endocrinol. 2024;20(2):93\u2013110.","journal-title":"Nat Reviews Endocrinol"},{"issue":"4","key":"8839_CR63","doi-asserted-by":"publisher","first-page":"188928","DOI":"10.1016\/j.bbcan.2023.188928","volume":"1878","author":"L Zhang","year":"2023","unstructured":"Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2023;1878(4):188928.","journal-title":"Biochim et Biophys Acta (BBA)-Reviews Cancer"},{"key":"8839_CR64","unstructured":"Halperin EC, Wazer DE, Baumann BC, Blitzblau RC, Esiashvili N, Perez. Brady, Halperin, and Wazer\u2019s Principles and practice of radiation oncology. Lippincott Williams & Wilkins; 2025."},{"issue":"9940","key":"8839_CR65","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet. 2014;384(9940):319.","journal-title":"Lancet"},{"issue":"8","key":"8839_CR66","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"8839_CR67","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825\u201335.","journal-title":"N Engl J Med"},{"issue":"8","key":"8839_CR68","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","volume":"20","author":"RI Haddad","year":"2022","unstructured":"Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(8):925\u201351.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"8839_CR69","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186(6):631\u201343.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"8839_CR70","first-page":"1","volume":"4","author":"W Zhang","year":"2022","unstructured":"Zhang W, Catanzaro JA, Khan SS. Individualized Therapeutic Design in Thyroid Disease: Strategies Through Genetic, Molecular, and Technological Innovations. J Precision Biosci. 2022;4(1):1\u201311.","journal-title":"J Precision Biosci"},{"issue":"1","key":"8839_CR71","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s12672-024-01677-8","volume":"15","author":"D Gulwani","year":"2024","unstructured":"Gulwani D, Upadhyay P, Goel R, Sarangthem V, Singh TD. Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine. Discover Oncol. 2024;15(1):789.","journal-title":"Discover Oncol"},{"key":"8839_CR72","doi-asserted-by":"crossref","unstructured":"Khatami F, Larijani B, Nikfar S, Hasanzad M, Fendereski K, Tavangar SM. Personalized treatment options for thyroid cancer: current perspectives. Pharmacogenomics and personalized medicine. 2019:235\u201345.","DOI":"10.2147\/PGPM.S181520"},{"issue":"10","key":"8839_CR73","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3390\/cancers15102692","volume":"15","author":"A Coca-Pelaz","year":"2023","unstructured":"Coca-Pelaz A, Rodrigo JP, Shah JP, Nixon IJ, Hartl DM, Robbins KT, et al. Recurrent differentiated thyroid cancer: the current treatment options. Cancers. 2023;15(10):2692.","journal-title":"Cancers"},{"issue":"1","key":"8839_CR74","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11154-023-09857-7","volume":"25","author":"E Abelleira","year":"2024","unstructured":"Abelleira E, Jerkovich F. Dynamic risk assessment in patients with differentiated thyroid cancer. Reviews Endocr Metabolic Disorders. 2024;25(1):79\u201393.","journal-title":"Reviews Endocr Metabolic Disorders"},{"key":"8839_CR75","doi-asserted-by":"crossref","unstructured":"Signore A, Lauri C, Di Paolo A, Stati V, Santolamazza G, Capriotti G et al. Predictive role of serum thyroglobulin after surgery and before radioactive iodine therapy in patients with thyroid carcinoma. Cancers. 2023;15:2976.","DOI":"10.3390\/cancers15112976"},{"issue":"4","key":"8839_CR76","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.ijrobp.2010.10.056","volume":"79","author":"A Puri","year":"2011","unstructured":"Puri A. Leibel and Phillips Textbook of Radiation Oncology. Int J Radiat Oncol Biol Phys. 2011;79(4):1276.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"8839_CR77","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1210\/jc.2015-2124","volume":"100","author":"HT Prinsen","year":"2015","unstructured":"Prinsen HT, Klein Hesselink EN, Brouwers AH, Plukker JT, Sluiter WJ, van der Horst-Schrivers AN, et al. Bone marrow function after 131I therapy in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metabolism. 2015;100(10):3911\u20137.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"1","key":"8839_CR78","first-page":"4376720","volume":"2016","author":"L Lu","year":"2016","unstructured":"Lu L, Shan F, Li W, Lu H. Short-term side effects after radioiodine treatment in patients with differentiated thyroid cancer. Biomed Res Int. 2016;2016(1):4376720.","journal-title":"Biomed Res Int"},{"key":"8839_CR79","unstructured":"Halperin EC, Brady LW, Wazer DE, Perez CA. Perez & Brady\u2019s principles and practice of radiation oncology. Lippincott Williams & Wilkins; 2013."},{"issue":"2","key":"8839_CR80","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ecl.2008.02.001","volume":"37","author":"JD Brierley","year":"2008","unstructured":"Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2):497\u2013509.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"8839_CR81","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.ijrobp.2008.09.023","volume":"74","author":"DL Schwartz","year":"2009","unstructured":"Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiation Oncology* Biology* Phys. 2009;74(4):1083\u201391.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"issue":"4","key":"8839_CR82","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/hed.24357","volume":"38","author":"AP Kiess","year":"2016","unstructured":"Kiess AP, Agrawal N, Brierley JD, Duvvuri U, Ferris RL, Genden E, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control: a statement of the American Head and Neck Society. Head Neck. 2016;38(4):493\u20138.","journal-title":"Head Neck"},{"issue":"1","key":"8839_CR83","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/COC.0000000000000455","volume":"42","author":"RJ Amdur","year":"2019","unstructured":"Amdur RJ, Dagan R. The University of Florida Department of Radiation Oncology guidelines for treatment of differentiated thyroid cancer with I-131 or external-beam radiotherapy. Am J Clin Oncol. 2019;42(1):92\u20138.","journal-title":"Am J Clin Oncol"},{"key":"8839_CR84","first-page":"101725","volume":"38","author":"M Ahmadi","year":"2024","unstructured":"Ahmadi M, Khorasani AM, Morshedzadeh F, Saffarzadeh N, Ghaderian SMH, Ghafouri-Fard S, et al. HLF is a promising prognostic, immunological, and therapeutic biomarker in human tumors. Biochem Biophys Rep. 2024;38:101725.","journal-title":"Biochem Biophys Rep"},{"issue":"9","key":"8839_CR85","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/iub.2338","volume":"72","author":"Z Mahboobeh","year":"2020","unstructured":"Hsu CY, Askar S, Alshkarchy SS, Nayak PP, Attabi KAL, Khan MA, et al. AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. Clin Exp Med. 2025;26(1):29.","journal-title":"IUBMB Life"},{"issue":"2","key":"8839_CR86","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/jcp.29950","volume":"236","author":"H Azari","year":"2021","unstructured":"Tomczak K, Czerwi\u0144ska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1a):A68\u201377.","journal-title":"J Cell Physiol"},{"issue":"7","key":"8839_CR87","doi-asserted-by":"publisher","first-page":"e70243","DOI":"10.1002\/mco2.70243","volume":"6","author":"T Wolde","year":"2025","unstructured":"Wolde T, Bhardwaj V, Pandey V. Current Bioinformatics Tools in Precision Oncology. MedComm. 2025;6(7):e70243.","journal-title":"MedComm"},{"key":"8839_CR88","doi-asserted-by":"crossref","unstructured":"Villanueva RAM, Chen ZJ. ggplot2: elegant graphics for data analysis. Taylor & Francis; 2019.","DOI":"10.1080\/15366367.2019.1565254"},{"issue":"22","key":"8839_CR89","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1093\/bioinformatics\/btab404","volume":"37","author":"H Wickham","year":"2021","unstructured":"Wickham H, Fran\u00e7ois R, Henry L, M\u00fcller K, Vaughan D. dplyr: a grammar of data manipulation.","journal-title":"Bioinformatics"},{"key":"8839_CR90","first-page":"1","volume":"09","author":"K Slowikowski","year":"2021","unstructured":"Slowikowski K, Schep A, Hughes S, Dang T, Lukauskas S, Irisson J. ggrepel: Automatically position non-overlapping text labels with \u2018ggplot2\u2019. R package version. 2021;09:1.","journal-title":"R package version"},{"key":"8839_CR91","unstructured":"Wickham H, Vaughan D, Girlich M. tidyr: Tidy Messy Data. R Package Version 1.3.1. 2024. Available from: https:\/\/CRAN.R-project.org\/package=tidyr. accessed 20 July 2025."},{"key":"8839_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","author":"Gao Jianjiong","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269). https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Science signaling"},{"issue":"W1","key":"8839_CR93","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"8839_CR94","doi-asserted-by":"publisher","first-page":"iyad031","DOI":"10.1093\/genetics\/iyad031","volume":"224","author":"SA Aleksander","year":"2023","unstructured":"Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, et al. The gene ontology knowledgebase in 2023. Genetics. 2023;224(1):iyad031.","journal-title":"Genetics"},{"issue":"D1","key":"8839_CR95","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa M, Furumichi M, Sato Y, Matsuura Y, Ishiguro-Watanabe M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 2025;53(D1):D672\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"8839_CR96","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52(D1):D672\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"8839_CR97","doi-asserted-by":"publisher","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","volume":"52","author":"I Rauluseviciute","year":"2024","unstructured":"Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2024;52(D1):D174\u201382.","journal-title":"Nucleic Acids Res"},{"key":"8839_CR98","unstructured":"Garnier S, Ross N, Rudis R, Camargo PA, Sciaini M, Scherer C. viridis-Colorblind-friendly color maps for R. R package version 06. 2021;2."},{"key":"8839_CR99","volume-title":"Patchwork: The composer of plots","author":"TL Pedersen","year":"2019","unstructured":"Pedersen TL. Patchwork: The composer of plots. CRAN: Contributed Packages; 2019."},{"issue":"W1","key":"8839_CR100","doi-asserted-by":"publisher","first-page":"W283","DOI":"10.1093\/nar\/gkaf423","volume":"53","author":"Y-J Kang","year":"2025","unstructured":"Kang Y-J, Pan L, Liu Y, Rong Z, Liu J, Liu F. GEPIA3: enhanced drug sensitivity and interaction network analysis for cancer research. Nucleic Acids Res. 2025;53(W1):W283\u201390.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"8839_CR101","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/1471-2105-15-293","volume":"15","author":"P Bardou","year":"2014","unstructured":"Bardou P, Mariette J, Escudi\u00e9 F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014;15(1):293.","journal-title":"BMC Bioinformatics"},{"key":"8839_CR102","doi-asserted-by":"crossref","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1).","DOI":"10.1093\/nar\/gkac1000"},{"issue":"11","key":"8839_CR103","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504.","journal-title":"Genome Res"},{"issue":"1","key":"8839_CR104","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/1471-2105-12-436","volume":"12","author":"JH Morris","year":"2011","unstructured":"Morris JH, Apeltsin L, Newman AM, Baumbach J, Wittkop T, Su G, et al. clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinformatics. 2011;12(1):436.","journal-title":"BMC Bioinformatics"},{"issue":"Suppl 4","key":"8839_CR105","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"C-H Chin","year":"2014","unstructured":"Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.","journal-title":"BMC Syst Biol"},{"issue":"22","key":"8839_CR106","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1093\/bioinformatics\/btq562","volume":"26","author":"J Montojo","year":"2010","unstructured":"Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, Donaldson SL, et al. GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics. 2010;26(22):2927\u20138.","journal-title":"Bioinformatics"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08839-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:04:16Z","timestamp":1790579056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08839-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8839"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08839-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This review article did not involve human participants, animal studies, or the use of patient data; therefore, ethical approval and consent to participate were not required.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All co-authors agreed to the submission of the current form of the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare that there are no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1214"}}